Recent research highlights the potential of CAR T cell therapies and bispecific antibodies in treating rheumatoid arthritis. These innovative approaches may offer new avenues for managing this chronic inflammatory disease.

A long-term study on early treat-to-target (TTT) strategies in rheumatoid arthritis shows promising outcomes, with a median change in radiographic damage score of just 2.0 points over 20 years. The study involved 230 patients and supports the recommendation for initial treatment based on clinical response.

A study from the French National Health Data System reveals the risk of demyelinating events linked to TNF-inhibitors in rheumatoid arthritis patients compared to conventional synthetic disease-modifying anti-rheumatic drugs. This research adds to the understanding of safety profiles for these treatments.

Amplio Pharma reports positive Phase 1b results for NovoBioJect, a formulation aimed at enhancing the efficacy of methotrexate for rheumatoid arthritis patients. Current methotrexate treatment achieves remission in only 40% of patients, highlighting the need for improved therapies.

AbbVie receives EU approval for a new pediatric indication of its drug, providing an oral treatment option for young patients with polyarticular juvenile idiopathic arthritis (pJIA). This expands the therapeutic options available for this patient population.